Previous 10 | Next 10 |
2024-02-29 05:51:00 ET Some investors are attracted to small biotech stocks because of their potential for explosive returns. It's not uncommon for these stocks to go parabolic after positive news is announced. That's exactly what happened to Iovance Biotherapeutics (NASDAQ: IOVA)...
Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer Amtagvi Regulatory Submissions on Track in the European Union, United Kingdom, and Cana...
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
2024-02-26 05:39:00 ET Investors looking for stocks that can produce swift and dramatic gains recently found what they wanted with Iovance Biotherapeutics (NASDAQ: IOVA) . Over the past three months, shares of the cancer drug developer nearly tripled in value. Despite an already...
2024-02-25 05:01:00 ET Iovance Biotherapeutics (NASDAQ: IOVA) just reached a huge milestone -- and investors have flocked to the stock, helping it to soar more than 70% in less than a week. What's the big news? The biotech company scored its first regulatory approval, from the U...
2024-02-23 15:00:00 ET More on the markets SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat SPY: The U.S. Is Positioned To Expand Its Global Dominance S&P 500: Correction In Progress, Deeper Selloff Expec...
2024-02-23 06:14:00 ET With shares of Iovance Biotherapeutics (NASDAQ: IOVA) soaring by 175% in the last three months, Wells Fargo analyst Yanan Zhu thinks they could still go as much as 47% higher. In fact, on Feb. 20, the analyst raised his price target for the stock from $17 ...
2024-02-23 00:04:26 ET Summary On February 16, the Food and Drug Administration granted an accelerated approval to Iovance Biotherapeutics' lifileucel or Amtagvi. This accelerated approval would make Amtagvi the first T-cell therapy for treating a solid tumor. I take a close l...
A look at the top 10 most actives in the United States Greenbrook TMS Inc. (GBNH) rose 64.9% to $0.32 on volume of 109,974,769 shares PROSHARES TRUST (SQQQ) rose 3.7% to $12.36 on volume of 106,443,308 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.7% to $4.825 on volume...
2024-02-21 13:09:13 ET DENVER, Colo., Feb 21, 2024 (www.247marketnews.com)- Midday Stocks to Watch; (NASDAQ: BREA ), (NASDAQ: VTYX ), (NYSE: WTTR ), (NASDAQ: IOVA ), (NASDAQ: EBS ) News Brera Holdings’ Strategic Victory: A Leap Forward for Mozambiq...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
The global retinoblastoma treatment market size was estimated to be $2.62 billion in 2023 and is expected to reach $4.20 billion by 2034 with a CAG...
SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating,...
SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leaders...